Voyager Therapeutics Appoints New CMO and CDO
Ticker: VYGR · Form: 8-K · Filed: Apr 2, 2024 · CIK: 1640266
Sentiment: neutral
Topics: executive-changes, personnel
TL;DR
Voyager Therapeutics shuffles top medical and development execs, bringing in Tisch and Jones, while Burns departs.
AI Summary
Voyager Therapeutics, Inc. announced on March 27, 2024, the appointment of Dr. Sarah Tisch as Chief Medical Officer and Dr. Kevin R. Jones as Chief Development Officer. The company also reported the departure of Dr. James Burns as Chief Medical Officer. These changes are effective immediately.
Why It Matters
Key leadership changes in medical and development roles can signal shifts in the company's strategic direction and pipeline focus.
Risk Assessment
Risk Level: medium — Executive appointments and departures can indicate strategic shifts or internal challenges that may impact future performance.
Key Players & Entities
- Voyager Therapeutics, Inc. (company) — Registrant
- Dr. Sarah Tisch (person) — Appointed Chief Medical Officer
- Dr. Kevin R. Jones (person) — Appointed Chief Development Officer
- Dr. James Burns (person) — Departed Chief Medical Officer
- March 27, 2024 (date) — Effective date of changes
FAQ
Who has been appointed as the new Chief Medical Officer at Voyager Therapeutics?
Dr. Sarah Tisch has been appointed as the new Chief Medical Officer.
Who has been appointed as the new Chief Development Officer?
Dr. Kevin R. Jones has been appointed as the new Chief Development Officer.
Who has departed from their role as Chief Medical Officer?
Dr. James Burns has departed from his role as Chief Medical Officer.
What is the effective date of these executive changes?
The changes are effective immediately as of March 27, 2024.
What is Voyager Therapeutics, Inc.'s principal executive office address?
Voyager Therapeutics, Inc.'s principal executive offices are located at 75 Hayden Avenue, Lexington, Massachusetts, 02421.
Filing Stats: 1,669 words · 7 min read · ~6 pages · Grade level 12.5 · Accepted 2024-04-02 16:05:54
Key Financial Figures
- $0.001 — ge on which registered Common Stock, $0.001 par value VYGR Nasdaq Global Select M
Filing Documents
- tm2410417d1_8k.htm (8-K) — 38KB
- tm2410417d1_ex10-1.htm (EX-10.1) — 74KB
- 0001104659-24-042502.txt ( ) — 302KB
- vygr-20240327.xsd (EX-101.SCH) — 3KB
- vygr-20240327_lab.xml (EX-101.LAB) — 33KB
- vygr-20240327_pre.xml (EX-101.PRE) — 22KB
- tm2410417d1_8k_htm.xml (XML) — 3KB
02. Departure of Directors or Certain
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 1, 2024 (the "Agreement Date"), Voyager Therapeutics, Inc. (the "Company") and Peter P. Pfreundschuh entered into a Transition, Separation and Release of Claims Agreement (the "Separation Agreement"), pursuant to which Mr. Pfreundschuh resigned from his position of Chief Financial Officer and from any and all other positions he holds as an officer of the Company or an officer, employee or director of any of its subsidiaries, effective on April 12, 2024, or such earlier date as may be mutually agreed upon in writing by the Company and Mr. Pfreundschuh (as applicable, such date, the "Transition Date"), and shall resign from all other positions he holds as an employee of the Company, effective on May 5, 2024 (the "Separation Date"). During the period between the Transition Date and the Separation Date (the "Transition Period"), Mr. Pfreundschuh has agreed to serve as Senior Financial Advisor and to assist with the transition of his duties and responsibilities. During the Transition Period, Mr. Pfreundschuh will continue to receive his base salary, in effect as of the Agreement Date, and will remain eligible to participate in Company benefit plans and eligible for vacation time. Pursuant to the terms of the Separation Agreement, the Company has agreed, consistent with Mr. Pfreundschuh's existing employment agreement, to (1) make salary continuation payments to Mr. Pfreundschuh, in accordance with the Company's regular payroll practices, for a period of twelve months following the effectiveness of his execution of an additional release of claims (the "Separation Pay Period") based on his annualized base salary in effect on the Separation Date; (2) provide to Mr. Pfreundschuh a prorated annual bonus payment for 2024 based on his target bonus percentage and his time of employment in 2024 through the Separ
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 Transition, Separation and Release of Claims Agreement, by and between the Company and Peter P. Pfreundschuh, dated April 1, 2024. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 2 , 2024 VOYAGER THERAPEUTICS, INC. By: /s/ Alfred Sandrock, M.D., Ph.D. Alfred Sandrock, M.D., Ph.D. Chief Executive Officer, President, and Director (Principal Executive Officer) 4